Pre-market Hot Trades in US Stocks

Top Kingwin, down 5.12% in pre-market trading, has no significant recent news. Trading is active with clear capital flow; considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Broadcom is up 3.17% in pre-market trading. Based on recent key news:

1. On December 6, Microsoft discussed custom chip collaboration with Broadcom, potentially shifting business from Marvell to Broadcom, driving up Broadcom's stock price. This move indicates that tech giants are accelerating their layout in the AI field, with Broadcom seen as a potential challenger to NVIDIA. Source: The Information

2. On December 8, demand for TPU chips from Broadcom's collaboration with Google increased, with the market expecting Broadcom's AI sales to surge by 147%, boosting the stock price. Investors are focused on AI business growth data and future performance guidance. Source: Citigroup

3. On December 8, analysts raised Broadcom's target price to $480, maintaining a "Buy" rating, reflecting market optimism regarding Broadcom's collaboration with Google. Source: Wedbush. AI chip demand is surging, and market sentiment is optimistic.

Top Gainers in Pre-market US Stocks

Cemtrex, up 228.66% in pre-market trading, has no significant recent news. Trading is active with clear capital flow; considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Treasure Gbl, up 109.71% in pre-market trading, has no significant recent news. Trading is active with clear capital flow; considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Fulcrum Therapeutics is up 78.20% in pre-market trading. Based on recent key news:

1. On December 8, Fulcrum Therapeutics announced that its experimental drug showed positive results in patients with sickle cell disease, leading to a rise in stock price. The drug demonstrated a significant increase in fetal hemoglobin levels in the early trials of the 20 mg dosage group, pushing the stock price up 49.4% in pre-market trading. Source: Reuters

2. On December 8, preliminary results from Fulcrum Therapeutics' PIONEER trial showed a significant increase in fetal hemoglobin in patients from the 20 mg dosage group, improving anemia and hemolysis markers, with the stock price rising 40% in pre-market trading. Source: Bloomberg

3. On December 6, Fulcrum Therapeutics granted new employees non-statutory stock options as a recruitment incentive, in compliance with NASDAQ listing rules. Source: EDGAR. The biopharmaceutical industry has performed strongly recently, with attention on regulatory dynamics